Neurocrine Biosciences Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Dec 01, 2022 / 05:35PM GMT
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst

All right. Welcome, everyone. This is Josh Schimmer from the Evercore ISI Biotech team. Please introduce our next company, Neurocrine Biosciences, Chief Executive Officer, Kevin Gorman; and Chief Financial Officer, Matt Abernethy. Gentlemen, welcome. Great to see you again. Thanks for your time.

Questions and Answers:

Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst

INGREZZA, powering through COVID, even though it feels like COVID is still impacting the psychiatry practice. Maybe give us a sense of what's worked so well as part of this recovery process or the segment of medicine that still seems very well known?

Kevin C. Gorman - Neurocrine Biosciences, Inc. - CEO & Director

Yes, Josh, it's a good question. And good to see you, too. And thank you very much to you and to Evercore for the opportunity to speak here. Before I get going,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot